

Results for announcement to the market		
Name of issuer	Rua Bioscience Limited	
Reporting Period	12 months to 30 June 2023	
Previous Reporting Period	12 months to 30 June 2022	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$682	5%
Total Revenue	\$682	5%
Net profit/(loss) from continuing operations	(\$5,959)	31%
Total net profit/(loss)	(\$5,959)	31%
Interim/Final Dividend		
Amount per Quoted Equity Security	No dividend has been declared	
Imputed amount per Quoted Equity Security	N/A	
Record Date	N/A	
Dividend Payment Date	N/A	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.06	\$0.06
A brief explanation of any of the figures above necessary to enable the figures to be understood	Rua's FY23 performance is set out in the company's announcement attached to this announcement, which provides more information on: operating and financial performance of the business and various other relevant aspects of the financial performance for the year ended 30 June 2023. No dividend has been declared for this period.	
Authority for this announcement		
Name of person authorised to make this announcement	Paul Naske, Chief Executive Officer	
Contact person for this announcement	Paul Naske, Chief Executive Officer	
Contact phone number	+64 21 445 154	
Contact email address	paul.naske@ruabio.com	
Date of release through MAP	29/08/2023	

Audited financial statements accompany this announcement.